AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects ...

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...